---
title: "Akari Therapeutics enters strategic ADC payload research collaboration with Whitehawk Therapeutics"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293474953.md"
description: "Akari Therapeutics has entered a strategic research collaboration with Whitehawk Therapeutics. The partnership aims to evaluate Akari's PH1 RNA splicing modulator ADC payload using Whitehawk’s TOP1i ADC platform. Planned preclinical studies will test dual-payload combinations for synergy, generating data to support next-generation antibody-drug conjugate (ADC) development opportunities."
datetime: "2026-07-22T12:40:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293474953.md)
  - [en](https://longbridge.com/en/news/293474953.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293474953.md)
generator: "portal-rs"
---

# Akari Therapeutics enters strategic ADC payload research collaboration with Whitehawk Therapeutics

-   Akari Therapeutics entered a strategic research collaboration with Whitehawk Therapeutics to evaluate its PH1 RNA splicing modulator ADC payload with Whitehawk’s TOP1i ADC platform. \* Planned preclinical studies will test dual-payload combinations for synergy, aiming to generate data to support next-generation ADC development opportunities. \* The partnership positions Akari’s PH1 platform for broader use beyond conventional ADC payload approaches as industry demand shifts toward differentiated payload innovation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220840PRIMZONEFULLFEED9766306) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [WHWK.US](https://longbridge.com/en/quote/WHWK.US.md)
- [AKTX.US](https://longbridge.com/en/quote/AKTX.US.md)

## Related News & Research

- [Akari Therapeutics participates in Virtual Investor “Why Now” on-demand conference webcast](https://longbridge.com/en/news/297190869.md)
- [Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy](https://longbridge.com/en/news/296250397.md)
- [Agree Realty director John Rakolta Jr acquires ADC common shares worth $1.47 million](https://longbridge.com/en/news/297505716.md)
- [Daiichi Sankyo doses first patient in Phase 1 trial of DS1025 CD25-targeted ADC for advanced solid tumors](https://longbridge.com/en/news/297172685.md)
- [Duality Biotherapeutics Strikes Billion-Dollar ADC Collaboration with Genentech](https://longbridge.com/en/news/297255082.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**